MARSEILLE, France–(Enterprise Wire)–Supervision Information:
Innate Pharma SA (OTC: ) (Euronext Paris: IPH; Nasdaq: IPHA) (innate or firm) introduced right this moment that members of its government staff plan to attend the upcoming assembly, particulars under. Members embody Yannis Morel, government vp and chief working officer, and Arvind Sood, government vp and president of U.S. operations.
- BTIG Digital Biotechnology Convention
date: August 5-6, 2024 | Digital
About Xiantian Pharmaceutical
Innate Pharma SA is a world clinical-stage biotechnology firm growing immunotherapies for sufferers with most cancers. Its revolutionary method goals to ship therapeutic antibodies and its ANKET® (AAntibody-based NK cells cell SecondRoar timetherapeutics) proprietary platform.
Innate’s product portfolio contains lead proprietary packages lacutamab in growth for cutaneous T-cell lymphoma and superior types of peripheral T-cell lymphoma, monalizumab for non-small cell lung most cancers in partnership with AstraZeneca (NASDAQ: ) , and ANKET ® multispecific NK cell engager to handle a number of tumor varieties.
Innate Pharma is a trusted companion for biopharmaceutical corporations resembling Sanofi (Nasdaq: ) and AstraZeneca, in addition to main analysis establishments, speed up innovation, analysis and growth to profit sufferers.
Innate Pharma is headquartered in Marseille, France, with U.S. workplaces in Rockville, Maryland, and is listed on Euronext Paris and NASDAQ in america.
To study extra about Innate Pharma, go to www.innate-pharma.com and observe us on LinkedIn and X.
Details about Innate Pharma inventory
|
ISIN code |
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer Relating to Ahead-Trying Data and Threat Elements
This press launch incorporates sure forward-looking statements, together with statements inside the that means of the Personal Securities Litigation Reform Act of 1995. Though the Firm believes that its expectations are primarily based on cheap assumptions, these forward-looking statements are topic to quite a few dangers and uncertainties, which may trigger precise outcomes to vary materially from expectations. These dangers and uncertainties embody, however are usually not restricted to, uncertainties inherent in analysis and growth, together with associated to security, the progress and outcomes of ongoing and deliberate medical trials and preclinical research, regulatory evaluate and approval of its product candidates , the Firm’s commercialization efforts and the Firm’s potential to proceed to boost capital to fund its progress. For an extra dialogue of the dangers and uncertainties that might trigger the Firm’s precise outcomes, monetary situation, efficiency or achievements to vary from these contained in forward-looking statements, please see the Normal Firm’s Threat Elements (Facteurs de Risque) part. To France Registration paperwork filed with the Authority for the Monetary Markets (AMF) (obtainable on the AMF web site at http://www.amf-france.org or on the Innate Pharma web site) and public paperwork and reviews filed with the U.S. Securities and Change Fee ( SEC), together with the Firm’s annual report on Type 20-F for the 12 months ended December 31, 2023, and subsequent paperwork and reviews filed by the Firm with the AMF or SEC or in any other case made public.
This press launch and the data contained therein doesn’t represent a proposal to promote Innate Pharma shares in any nation, nor does it represent a solicitation of a proposal to purchase or subscribe for Innate Pharma shares.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20240731971255/en/
For extra info please contact:
investor
Xiantian Pharmaceutical
Henry Wheeler
Tel: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
media relations
new capital
Arthur Ruyer
Tel: +33 (0)1 44 71 00 15
innate@newcap.eu
Supply: Innate Pharma
